Related Experiment Video
Updated: Feb 2, 2026
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
Early aggressive intervention for infantile atopic dermatitis to prevent development of food allergy: a multicenter,
Kiwako Yamamoto-Hanada1, Tohru Kobayashi2, Hywel C Williams3
11Allergy Center, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo, 157-8535 Japan.
Insights
Early aggressive treatment for infants with atopic dermatitis may prevent the development of food allergies. This randomized controlled trial investigates if intensive intervention can reduce the incidence of hen’s egg allergy.
Area of Science:
- Allergy and immunology research
- Dermatology and skin health
- Pediatric health and development
Background:
- Atopic dermatitis (AD) is the initial manifestation of the atopic march, frequently appearing in the first year of life.
- Infants with AD often progress to other allergic conditions, including food allergy, asthma, and allergic rhinitis.
- A defective skin barrier in early AD may facilitate food sensitization.
Purpose of the Study:
- To test the hypothesis that aggressive early intervention for new-onset atopic dermatitis can prevent subsequent allergen sensitization.
- To evaluate the efficacy of early intensive AD treatment in preventing the development of food allergy, asthma, and allergic rhinitis.
- To assess the potential impact of this strategy on reducing the incidence and healthcare costs associated with food allergies.
Main Methods:
- A multi-center, pragmatic, randomized controlled trial (RCT) involving 650 infants aged 7-13 weeks with recent-onset atopic dermatitis.
- Participants were randomly assigned (1:1) to either aggressive treatment or conventional treatment for their atopic dermatitis.
- The primary endpoint was the development of IgE-mediated hen's egg allergy, confirmed by oral food challenge at 28 weeks of age.
Main Results:
- This section is not available in the provided abstract.
Conclusions:
- This pragmatic RCT is a novel approach to investigate the efficacy of early, aggressive atopic dermatitis treatment in preventing food allergy.
- Positive findings could lead to a new disease prevention strategy, particularly in regions with high food allergy prevalence.
- Further long-term follow-up and similar studies are needed to determine if this approach can reduce the burden of other allergic diseases like asthma and allergic rhinitis.
Background:
Atopic dermatitis is the first clinical manifestation of the atopic march, with the highest incidence in the first year of life. Those affected often go on to develop other allergic diseases including food allergy, asthma, and allergic rhinitis. Recent evidence suggests that sensitization to foods may occur through a defective skin barrier which is common in atopic dermatitis in early life. We hypothesize that therapeutic aggressive intervention to treat new onset atopic dermatitis may prevent the development of later allergen sensitization, and associated food allergy, asthma, and allergic rhinitis.
Methods:
This study is a multi-center, pragmatic, two-parallel group, assessor-blind, superiority, individually randomized controlled trial. Atopic dermatitis infants (N = 650) 7-13 weeks old who develop an itchy rash within the previous 28 days are randomly assigned to the aggressive treatment or the conventional treatment in a 1:1 ratio. The primary outcome is oral food challenge-proven IgE-mediated hen's egg allergy at the age of 28 weeks.
Discussion:
This is a novel pragmatic RCT study to examine the efficacy of early aggressive treatment for atopic dermatitis to prevent later food allergy. If our hypothesis is correct, we hope that such a strategy might impact on disease prevention in countries where food allergy is common, and that our results might reduce the frequency and associated costs of all food allergies as well as hens egg food allergy. Long-term follow and other similar studies will help to determine whether such a strategy will reduce the burden of other allergic diseases such as asthma and allergic rhinitis.Trial registration UMIN-CTR: UMIN000028043.
Related Concept Videos
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
01:11Clinical Trials: Overview
01:12Trial and Error and Algorithm
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:04Random Error
01:09Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...